

# **Synthesis and Bioactivity of Albicidin Analogues with Amide Bond Isosteres**

**2021.10.02 Literature Seminar  
B4 Hiromu Kakizawa**

# Contents

- 1. Introduction of albicidin and its bioactivity**
  
- 2. Synthesis and bioactivity of albicidin analogues with amide bond isosteres  
(*Org. Lett.* 2021, 23, 7023-7027)**


# Contents

**1. Introduction of albicidin and its bioactivity**

**2. Synthesis and bioactivity of albicidin analogues  
with amide bond isosteres  
(*Org. Lett.* 2021, 23, 7023-7027)**

# Albicidin (1)

- Isolated in 1985, from *Xanthomonas albilineans* (by Patil)<sup>1)</sup>
- Structure determination and total synthesis in 2015 (by Süssmuth)<sup>2) 3)</sup>  
Acyl pentapeptide composed of six building blocks (A-F), mainly aromatic characters.
- **DNA gyrase inhibition activity:**<sup>4)</sup>  
Antibacterial activity at nanomolar concentrations against a range of gram-positive and gram-negative bacteria.  
Also blocks chloroplast of plants, causing sugarcane leaf scald.




1) Birch, R; Patil, S. *J. Gen. Microbiol.* **1985**, *131*, 1069-1075. 2) Cociancich, S.; Pesic, A.; Petras, D.; Uhlmann, S.; Kretz, J.; Schubert, V.; Vieweg, L.; Duplan, S.; Marguerettaz, M.; Noëll, J.; Pieretti, I.; Hügelland, M.; Kemper, S.; Mainz, A.; Rott, P.; Royer, M.; Süssmuth, R. *Nat. Chem. Biol.* **2015**, *11*, 195-197. 3) Krets, J.; Kerwat, D.; Schubert, V.; Grätz, S.; Pesic, A.; Semsary, S.; Cociancich, S.; Royer, M.; Süssmuth, R. *Angew. Chem. Int. Ed.* **2015**, *54*, 1969-1973. 4) Hashimi, S.; Wall, M.; Smith, A.; Maxwell, A.; Birch, R. *Antimicrob. Agents Chemother.* **2007**, *51*, 181-187.


# Various Analogues of 1 with Compatible antibacterial activity

At least 10 analogues of 1 have been discovered in nature so far, partly using mass spectrometric networking.<sup>1) 2)</sup>

Like albicidin (**1**), many of these analogues exhibit antibacterial activity, implying biological value of this structure.



Similar MS/MS spectra are connected through lines and form molecular networks. Near the center is the original albicidin, and its analogues are detected as nodes.




Discovered from MS/MS networking or isolated from nature


1) Eckardstein, L.; Petras, D.; Dang, T.; Cociancich, S.; Sabri, S.; Grätz, S.; Kerwat, D.; Seidei, M.; Pesic, A.; Dorresteijn, P.; Royer, M.; Weston, J.; Süssmuth, R. *Chem. Eur. J.* **2017**, 23, 15316-15321. 2) Cheng, B.; Müller, R.; Trauner, D. *Angew. Chem. Int. Ed.* **2017**, 56, 12755-12759.

# DNA Gyrase as a Drug Target

DNA gyrase is an enzyme for the **relaxation of positive supercoils** of DNA and the **introduction of negative supercoils** to DNA.




Negative supercoils of DNA are essential in DNA replication and transcription, and therefore the inhibition of DNA gyrase leads to cell death. There are some molecules which selectively inhibit DNA gyrase of bacteria and do not affect mammalian cells, and thus DNA gyrase has been regarded as a drug target.



# Inhibition of DNA Gyrase


Coumarin antibiotics: inhibition of ATPase reaction of gyrase




Coumermycin A<sub>1</sub>

Resistance mutation: *gyrB*

Quinolone antibiotics: formation of gyrase-quinolone-DNA complex



Nalidixic acid



Ciprofloxacin


Resistance mutation:  
*gyrA* and *gyrB*

These exhibit antibacterial activity against a range of bacteria, but due to development of antibacterial resistance, there has been an urgent need for novel antibiotics.

1) Collin, F.; Karkare, S.; Maxwell, A. *Appl. Microbiol. Biotechnol.* 2011, 92, 479–497.

# DNA Gyrase Inhibition Activity of 1

## Inhibition assay of DNA gyrase



Each concentrations of Albicidin (**1**) + relaxed DNA +

A: DNA gyrase (*E. coli* MG1665 wild type)

B: DNA gyrase (quinolone-resistant *E. coli* mutant)

CFX lane: ciprofloxacin instead of **1**

< upper band: Relaxed DNA

< lower band: Supercoiled DNA

Disappearance of lower band represents successful inhibition of DNA gyrase.

**1** inhibited supercoiling of DNA catalyzed by *E. coli* DNA gyrase, with an IC<sub>50</sub> ≈ 40 nM.

Although the efficiency declined (IC<sub>50</sub> ≈ 200 nM), **1** also inhibited DNAgyrase from quinolone-resistant *E. coli*.

# Antibacterial Activity of 1

Antibacterial activity (with ciprofloxacin, a fluoroquinolone antibiotic)


Strain	MIC value ( $\mu\text{g/mL}$ )	
	1	Ciprofloxacin
<i>E. coli</i>	0.031	0.015
<i>E. coli</i> (qnrA1 mutation*)	0.063	32
<i>E. coli</i> (gyrA1 mutation*)	0.5	> 64
<i>S. enteritidis</i>	0.5	0.031
<i>P. aeruginosa</i>	1	0.5
<i>S. aureus</i>	16	0.5
<i>M. luteus</i>	1	not determined

\* fluoroquinolone resistant mutations

Albicidin (1) exhibited potent antibacterial activity against the **fluoroquinolone-resistant** bacteria strains as well.

# Enzymatic Hydrolysis of 1 by AlbD


AlbD (Albicidin detoxification enzyme): endopeptidase expressed in *Pantoea dispersa*



AlbD catalyzes hydrolysis of amide bond between D and E building blocks, causing a complete loss of DNA gyrase inhibition activity of albicidin.

# Attempted Substitution of D-E Linkage

To overcome AlbD, four analogues with substituted D-E linkage were synthesized.



MIC values ( $\mu\text{g/mL}$ ) of **1** and **1** analogues

	original ( <b>1</b> )	triazole	sulfonamide	urea	<i>N</i> -methyl amide
<i>E. coli</i> DSM1116	0.063	0.063	8.0	2.0	8.0
<i>S. typhimurium</i> TA100	0.063	0.125	0.50	8.0	8.0
<i>S. subillis</i> DSM10	0.25	4.0	8.0	8.0	8.0

\* The bacteria species used in this assay do not express AlbD.

Although substituting the AlbD-labile amide bond avoided hydrolysis by AlbD, it led to a decreased antibacterial activity. Further exploration for isosteres remained necessary.

# Contents

**1. Introduction of albicidin and its bioactivity**

**2. Synthesis and bioactivity of albicidin analogues  
with amide bond isosteres**  
**(*Org. Lett.* 2021, 18, 7023-7027)**

# Prof. Roderich Süssmuth




- 1995      B.S. @ University of Tübingen (Professor G. Jung)**
- 1996-     Research Associate  
              @ Institute of Organic Chemistry, University of Tübingen**
- 1999      Ph.D. @ University of Tübingen (Professor G. Jung)**
- 2000-     Visiting Scientist Fellowship @ The Scripps Research Institute  
              (Professor R.A. Lerner and Prof. C.F. Barbas)**
- 2001-     Emmy-Noether-Research Fellow @ University of Tübingen**
- 2004-     Associate Professor @ Technical University Berlin**
- 2008-     Full Professor @ Technical University Berlin**

**Research interests:**

- Bioactive secondary metabolites
- Total synthesis of natural compounds
- Structure-activity relationships for a design of potent future drugs

# Further Exploration for Isosteres

Isosteric replacements of D and E building blocks



- Alkane linkage (2)
- Alkene linkage (3)
- Alkyne linkage (4)


... For enhanced stability against chemical and enzymatic hydrolysis

## Isosteres



- Fluoroalkene linkage (5)

... A well-known isostere of amide bond with sterically and electrically similarity




- D ring substituted with benzofuran (6)
- E ring substituted with benzimidazole (7)

... For reduced structural flexibility

# Synthesis of Six Isosteres


Albicidin isosteres (**2-7**) to be synthesized



**PG = Protecting Group**


\***Aza-histidine** was used as C building block instead of Cyanoalanine, which have an optimized antibacterial profile and a higher chemical stability.<sup>1)</sup>

Synthetic method for each isosteric moiety




**Alkane (2), Alkene (3), Fluoroalkene (5):**  
Pd-catalyzed cross coupling

**Alkyne (4): Pd-Cu-catalyzed Sonogashira coupling**



**Benzofuran (6):**  
Sonogashira coupling  
followed by Pd-Cu-catalyzed intramolecular annulation




**Benzimidazole (7):**  
Reaction between o-phenylenediamine and benzaldehyde

1) Behroz, I.; Durkin, P.; Grätz, S.; Seidel, M.; Rostock, L.; Spinczyk, M.; Weston, J.; Süßmuth, R. *Chem. Eur. J.* **2019**, 25, 16538-16543.

# Strategies for the Synthesis of 1 Analogues (1)


- Coupling order of each unit



**restricted solubility by the introduction of A block<sup>1)</sup>**

**risk of racemization of C block during the reactions<sup>2)</sup>**

Introduction of these moiety in the late stage enabled to minimize the risk of troubles.



1) Krets, J.; Kerwat, D.; Schubert, V.; Grätz, S.; Pesic, A.; Semsary, S.; Cociancich, S.; Royer, M.; Süßmuth, R. *Angew. Chem. Int. Ed.* **2015**, 54, 1969-1973. 2) Eckardstein, L.; Petras, D.; Dang, T.; Cociancich, S.; Sabri, S.; Grätz, S.; Kerwat, D.; Seidei, M.; Pesic, A.; Dorrestein, P.; Royer, M.; Weston, J.; Süßmuth, R. *Chem. Eur. J.* **2017**, 23, 15316-15321.

# Synthetic Strategies for the of 1 Analogues (2)


- Strategy of condensation reagent

Low nucleophilicity of **aromatic amine** required harsh conditions for amide formation.

At the same time, it was necessary to avoid ***E/Z* isomerization** and **racemization** in some substrates.


To avoid *E/Z* isomerization...

Relatively mild conditions, **Oxalyl chloride ( $\text{COCl}_2$ )** was applied.



To avoid racemization...

**EEDQ** was applied, which is known for its low rates of racemization.<sup>1)</sup>



1) Krets, J.; Kerwat, D.; Schubert, V.; Grätz, S.; Pesic, A.; Semsary, S.; Cociancich, S.; Royer, M.; Süßmuth, R. *Angew. Chem. Int. Ed.* **2015**, 54, 1969-1973.

# Synthetic Strategies for the of 1 Analogue (3)


- Protecting group strategy

For the free phenol and carboxylic acid (O-PG)

PG = Bn





For global deprotection and hydrogenation at the same time



Stable under Pd-catalyzed coupling conditions

PG = Allyl



Unstable to Bn deprotection conditions ( $H_2$ , Pd/C) due to unsaturated bonds


PG = MOM, *t*-Bu, etc. (acid-labile protecting groups)

Not applied (very inefficient deprotection for steric hinderance)



For the amine moiety (R)

$NO_2$  group was applied



(For atom economy and deprotection under mild conditions (Zn, AcOH))





# Construction of D-E-F Unit: Alkane Isostere (2)




# Construction of D-E-F Unit: Alkene And Fluoroalkene Isosteres (3 and 5)




# Construction of D-E-F Unit: Alkyne Isostere (4)





# Construction of D-E-F Unit: Benzofuran Isostere (6)



# Construction of D-E-F Unit: Benzimidazole Isostere (7)




# Coupling of D-E-F Unit to C Unit




**2:** 72 %, **3:** 77 %  
**4:** 64 %, **5:** 89 %  
**6:** 53 %, **7:** 75 %

C unit was constructed via Click reaction, which was condensed with all of the six D-E-F unit of each analogues in good to moderate yield.


# Deprotection of Allyl, Bn, And Boc Group



Global deprotection and hydrogenation (for isostere **2**)



# Coupling of A-B Unit



When coupling of original A-B unit was tried for benzofuran isostere, no desired compound was obtained. Therefore, an alternative A-B unit (shown above) was used.

# Bioactivity of Albicidin Isosteres

MIC value ( $\mu\text{g/mL}$ ), stability against AlbD, and gyrase inhibition activity


bacterial strain									
<i>E. coli</i> BW25113	0.063	0.125	8.0	0.25	0.125	0.063	0.063	1.0	0.25
<i>S. typhimurium</i> TA100	0.063	0.125	0.5	0.25	0.063	$\leq 0.016$	0.031	0.125	0.063
<i>B. subtilis</i> DSM10	0.250	4.0	8.0	0.063	0.063	0.063	0.031	0.25	2.0
<i>M. phlei</i> DSM750	2.0	8.0	8.0	1.0	0.50	0.50	0.250	1.0	8.0
<i>E. coli</i> DSM1116	0.016	0.063	8.0	0.25	0.125	0.063	0.063	2.0	0.25
<i>M. luteus</i> DSM1790	0.5	8.0	8.0	0.125	0.25	0.25	0.063	0.25	8.0
AlbD stability	✗	✓	✓	✓	✓	✓	✓	n.d.	✓
<i>E. coli</i> gyrase inhibition	n.d.	↓	↓	≈	↑	↑	↑	↓	↓

- The isosteres showed antibacterial activity even in the presence of AlbD.
- Introduction of alkyne and fluoroalkene linkage increased antibacterial activity.

# Summary

Original albicidin:


potent antibacterial activities even against  
fluoroquinolone-resistant bacteria, but  
readily hydrolyzed with the enzyme AlbD



Three synthetic strategies:


- 1) Coupling order of each unit
- 2) Careful choice of condensation reagent
- 3) Protecting group strategy

Amide isosteres which can  
overcome AlbD while maintaining  
potent antibacterial activity:




# Appendix

# Structures of Various Analogues of 1



	<b>R<sup>1</sup></b>	<b>R<sup>2</sup></b>	<b>R<sup>3</sup></b>	<b>R<sup>4</sup></b>	<b>R<sup>5</sup></b>	<b>R<sup>6</sup></b>
<b>1</b>	OH	CN	H	Me	OH	OH
carbamoyl-1	OCONH <sub>2</sub>	CN	H	Me	OH	OH
F-dehydroxy-1	OH	CN	H	Me	OH	H
β-OMe-Cya-1	OH	CN	OMe	Me	OH	OH
β-OMe-Asn-1	OH	CONH <sub>2</sub>	OMe	Me	OH	OH
cystobactamid 919-2	OH	CONH <sub>2</sub>	OMe	i-Pr	OH	H
coralmycin	OH	CONH <sub>2</sub>	OMe	i-Pr	OH	OH





Found by mass spectrometric networking <sup>1)</sup>

Isolated by Kim In 2016 <sup>2)</sup>

1) Eckardstein, L.; Petras, D.; Dang, T.; Cociancich, S.; Sabri, S.; Grätz, S.; Kerwat, D.; Seidei, M.; Pesic, A.; Dorrestein, P.; Royer, M.; Weston, J.; Süssmuth, R. *Chem. Eur. J.* 2017, 23, 15316-15321. 2) Kim, Y.; Kim, H.; Kim, G.; Cho, S.; Takahashi, S.; Koshimo, H. *Nat. Prod.* 2016, 79, 2223-2228.


# Strategy for Total Synthesis of Albicidin




Introduction of A unit in the early stage of synthesis resulted in low solubility of compound, so A-B bond was formed in the last step.

# Construction of A Unit And B-C-D Unit


A unit




B-C-D unit




# Construction of E-F Unit




# Coupling of B-C-D Unit



# Total Synthesis of 1



# Modified Synthetic Strategy for 1




# AlbD Assay for Albicidin Analogues (2019)

*E. coli* DSM1116 with LB agar

Positive control:


100µM albicidin

(or analogue) with buffer



AlbD reaction mixture:  
10µM AlbD and 100µM  
albicidin (or analogue) with buffer

Negative control:  
10µM AlbD with buffer




# AlbD assay for Albicidin Analogues (2021)

*E. coli* DSM1116 with LB agar

Positive control:


100 $\mu$ M albicidin

(or analogue) with buffer



AlbD reaction mixture:  
10 $\mu$ M AlbD and 100 $\mu$ M  
albicidin (or analogue) with buffer

Negative control:  
10 $\mu$ M AlbD with buffer



# *E. coli* DNA gyrase inhibition assay

relaxed pBR322 plasmid + *E. coli* DNA gyrase + albicidin or each analogue

